XML 35 R22.htm IDEA: XBRL DOCUMENT v3.6.0.2
License Agreement - Narrative (Details) - USD ($)
$ in Thousands
9 Months Ended
Apr. 29, 2016
Dec. 31, 2016
Class of Warrant or Right [Line Items]    
Shares issued to Takeda under the Takeda license agreement (in shares) 5,077,001  
Period for which royalties are required to be paid after the first commercial sale of relugolix or MVT-602 products   10 years
Ownership percentage to which the warrants entitle Takeda   12.00%
Purchase of in-process research and development expense $ 13,100 $ 13,117
Research and development expense related to intellectual property and inventory with no alternative for future use, portion related to fair value of common shares issued 7,700 $ 7,740
Warrant liability $ 5,400  
Maximum    
Class of Warrant or Right [Line Items]    
Warrant term   1 year